Alnylam Pharmaceuticals, Inc of Cambridge, Massachusetts has concluded a new technology transfer and research alliance in the field of RNA interference (RNAi) therapeutics, confirming the importance of this technology for future drug development. ---Subscribe to MedNous to access this article--- Company News
